PSORENT Psoriasis Topical Solution
A steroid-free topical treatment to help relieve itching, scaling, redness and other psoriasis symptoms. Psorent is clinically proven to be significantly more effective than the leading* prescription-strength psoriasis cream in improving and controlling the symptoms of plaque psoriasis.
  • 15% liquor carbonis distillate (LCD) in a fast-absorbing, quick-drying formulation
  • Convenient dab-on topical delivery system with no-mess applicator
  • Can be used on scalp psoriasis
  • *Data on file, NeoStrata Company, Inc.
Item #: 8960

Psorent is a clinically-proven psoriasis treatment to help relieve the itching, scaling, flaking, redness, irritation and other psoriasis symptoms. This steroid-free formulation is fast-drying and applies easily with a convenient, no-mess applicator. The dab-on delivery system allows for direct application without touching either the solution or the psoriasis plaque, and avoids stains, odor and messiness. 15% liquor carbonis distillate (LCD) is absorbed quickly into the skin, while a liquid wax creates a light-occlusive barrier on psoriatic plaques and significantly reduces the odor and staining associated with traditional coal tar products.

Recommended usage: Twice Daily AM/PM, as tolerated

Key ingredients: Liquor Carbonis Distillate (LCD)

Size: 3.4 fl oz. One bottle is approximately a 90-day supply for mild to moderate psoriasis depending on the severity and surface area.

Insider Tip! Use NeoStrata Problem Dry Skin Cream to soften psoriasis plaques before using Psorent.

90-day challenge money back guarantee!
Use Psorent twice a day, every day for at least 4 weeks to see results. After 90 days, if you're not satisfied, you may return it to us for a full refund.
Apply to affected areas one to two times daily or as directed by a doctor. Dab gently onto affected skin to start the flow of medication. Apply just enough medication to wet the skin and avoid dripping. Avoid applying to severely cracked or irritated areas. Allow solution to fully dry before dressing to avoid staining clothing. Do not rinse off treated skin. Cap bottle tightly after use.

Scalp Psoriasis
Scalp psoriasis is reported to occur in 50-80% of psoriasis sufferers and is categorized by having psoriasis plaques under the hair on the scalp and can extend past the hairline to the neck, forehead and around the ears. Scalp psoriasis is recognized by its silver-white scaling, redness, flaking and itch on or around the scalp. Extreme dandruff, dry scalp and seborrheic dermatitis of the scalp are usually categorized with psoriatic scalp because they present many of the same symptoms. Product attributes need to be taken into consideration when treating psoriasis of the scalp such as application, odor, and hair staining. The treatment for scalp psoriasis is somewhat difficult because of the presence of the hair (especially since most sufferers prefer to keep longer hair to hide the redness of the condition). Luckily, Psorent psoriasis topical solution is the ideal medium for treating scalp psoriasis. Its no-mess applicator allows the user to precisely dab the product to affected areas. Psorent has the consistency of water, so it doesn’t stick to the hair like creams or conditioners; it works directly on the skin where it is needed.

Psorent was tested on medium blond and bleached blonde hair in an aggregated application study and no staining was seen, however, we recommend that processed hair (color, perm, relaxers, etc.) and gray hair, spot treat an inconspicuous area of the scalp before treating the entire area. This allows to test for staining, as individual cases may differ. Data on file, NeoStrata Company, Inc.
Active: Coal Tar 2.3% (from Coal Tar Topical Solution, USP 15%)
Inactive: Cyclomethicone, Dioctyldodecyl Dodecanedioate, Ethyl Alcohol, Fragrance, Polyoxyethylene (2) Oleyl Ether, Propylene glycol, Triethyl Citrate.
PRNewswire, March 8, 2009 - A nonprescription topical solution made with a new formulation of liquor carbonis distillate (LCD), known as PSORENT®, is significantly more effective than prescription-strength calcipotriol cream in improving and controlling the symptoms of plaque psoriasis. Significant efficacy differences favoring LCD solution over a 12-week treatment phase were also pronounced after treatment stopped, during a 6-week regression phase. The research, a randomized, investigator-blind, active-controlled study of 60 adults with moderate plaque psoriasis, was conducted by a team of investigators at the Clinical Unit for Research Trials in Skin (CURTIS) at Massachusetts General Hospital in Boston, MA. The team's conclusions are based on data from 55 patients who received treatment for up to 12 weeks and 43 patients who returned for re-assessment 6 weeks after treatment stopped. Its main findings include:
• LCD therapy produced a significantly better reduction in psoriasis severity than calcipotriol therapy in 12 weeks based on PASI 50 (67% vs. 36%) and PASI 75 (37% vs. 0%) achievers and percent change in PASI (58% vs 37%) and PGA scores (P<0.05). • Significantly fewer LCD-treated patients than calcipotriol-treated patients regressed to initial disease severity within 6 weeks of stopping treatment (P<=0.005). • PASI scores and PGA scores worsened significantly after stopping calcipotriol therapy but not after stopping LCD therapy (P<=0.05).

Within 6 weeks of completing treatment, LCD-treated patients reported better control of a range of psoriasis symptoms - including scaling/flaking, redness, skin texture, itch, overall appearance, and overall discomfort - than calcipotriol-treated patients. Patients' rated LCD solution and calcipotriol cream as comparable for convenience, irritation potential, and aesthetic attributes (e.g., staining, scent).

Data on file, NeoStrata Company, Inc.

You Might Also Like

Customer Reviews